Led by strong sales of its Impella devices, Abiomed reported on May 3 that its revenue increased 43 percent to $329.5 million during fiscal year 2016 compared with fiscal year 2015. For the fourth quarter, revenue increased 39 percent to $94.0 million, the 26th consecutive quarter that Abiomed’s revenue has increased by at least 10 percent year-over-year.

Abbott Laboratories is set to acquire St. Jude Medical in a cash and stock transaction valued at approximately $25 billion.

During the first quarter of 2016, Boston Scientific reported sales of $1.964 billion, a 13 percent increase from the same period last year. The company had adjusted earnings per share of $0.28 per share, up from $0.21 per share a year ago. Boston Scientific also raised its revenue and earnings guidance for the full year.

For the first quarter of fiscal year 2016, St. Jude Medical’s net sales increased 8 percent to $1.448 billion and its adjusted earnings increased 9 percent to $0.90 per share from the first quarter of last year.

Medtronic announced it had tendered approximately $5.8 billion in aggregate principal of outstanding debt securities as of 5:00 p.m. Eastern time on April 13, the early deadline for a previously announced tender offer.

From 2002 to 2013, the mean price of insulin increased 197 percent, from $4.34 per milliliter to $12.92 per milliliter, according to a survey of more than 27,000 people treated for diabetes.

The Centers for Medicare and Medicaid Services (CMS) have proposed banning Theranos founder Elizabeth Holmes and president Sunny Balwani from owning or running a blood-testing lab for at least two years.

After the U.S. Department of Treasury issued temporary and proposed regulations on tax inversions and other related topics, Medtronic announced in a news release on April 6 that the regulations “do not have a material financial impact on any transaction undertaken by the company.”